Connection

Andrew Kraft to Female

This is a "connection" page, showing publications Andrew Kraft has written about Female.
Connection Strength

0.191
  1. Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report. J Med Case Rep. 2021 Jul 24; 15(1):400.
    View in: PubMed
    Score: 0.040
  2. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.
    View in: PubMed
    Score: 0.038
  3. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget. 2017 May 02; 8(18):30199-30216.
    View in: PubMed
    Score: 0.030
  4. Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study. Melanoma Res. 1999 Dec; 9(6):599-606.
    View in: PubMed
    Score: 0.009
  5. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999 Jan 01; 85(1):178-87.
    View in: PubMed
    Score: 0.008
  6. PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. J Clin Invest. 2018 07 02; 128(7):2787-2801.
    View in: PubMed
    Score: 0.008
  7. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res. 1996 Feb 15; 56(4):802-8.
    View in: PubMed
    Score: 0.007
  8. Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res. 2015 Dec 15; 75(24):5318-28.
    View in: PubMed
    Score: 0.007
  9. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82.
    View in: PubMed
    Score: 0.006
  10. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. J Hematol Oncol. 2013 Jan 29; 6:12.
    View in: PubMed
    Score: 0.006
  11. Role of thoracic radiotherapy combined with chemotherapy in limited stage small cell lung cancer (SCLC). A randomized multicenter phase III trial. Onkologie. 1990 Aug; 13(4):253-8.
    View in: PubMed
    Score: 0.005
  12. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3133-40.
    View in: PubMed
    Score: 0.004
  13. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 08; 52(1):74-86.
    View in: PubMed
    Score: 0.004
  14. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. 2007 Dec 20; 7:231.
    View in: PubMed
    Score: 0.004
  15. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 03; 7:221.
    View in: PubMed
    Score: 0.004
  16. Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol Ther. 2006 Aug; 5(8):1015-21.
    View in: PubMed
    Score: 0.004
  17. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 2005 Apr 01; 103(7):1431-8.
    View in: PubMed
    Score: 0.003
  18. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res. 1999 Sep; 5(9):2344-8.
    View in: PubMed
    Score: 0.002
  19. Enolase isoenzymes as tumour markers. J Clin Chem Clin Biochem. 1986 Dec; 24(12):1009-16.
    View in: PubMed
    Score: 0.001
  20. [Neo-adjuvant chemotherapy of head and neck cancer]. Dtsch Med Wochenschr. 1986 Jul 11; 111(28-29):1097-100.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.